Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276237 | 0.82 | ALDH1A1 (0.50) | KDM4ELMNAGAAJAK2MAPT | |
| SCHEMBL500049 | 0.82 | LMNA (0.50) | CYP1A2KDM4ELMNAAGTR1GAA | |
| SCHEMBL9798227 | 0.80 | KDM4E (0.36) | CYP1A2KDM4ELMNAAGTR1GAA | |
| SCHEMBL525307 | 0.78 | KDM4E (0.34) | CYP1A2KDM4ELMNAAGTR1GAA | |
| SCHEMBL93705 | 0.76 | ALDH1A1 (0.56) | CYP1A2KDM4EGAAMAPTCYP2C19 | |
| SCHEMBL2769030 | 0.76 | DRD1 (0.42) | CYP1A2KDM4ELMNAAGTR1GAA | |
| SCHEMBL2536766 | 0.76 | KDM4E (0.33) | KDM4ELMNAGAAJAK2MAPT | |
| SCHEMBL9217603 | 0.76 | KDM4E (0.33) | KDM4ELMNAGAAJAK2MAPT | |
| SCHEMBL7474927 | 0.76 | KDM4E (0.43) | CYP1A2KDM4ELMNAGAAJAK2 | |
| SCHEMBL21724382 | 0.76 | MEN1 (0.39) | KDM4ELMNAGAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093354-A1 | METHOD OF REDUCING OR PREVENTING MALODOUR | UNILEVER PLC (GB) | 2001-04-25 | — | — | EP | claimed |
| US-6171582-B1 | TOPICALLY APPLYING TO HUMAN SKIN AN ACTIVE AGENT CAPABLE OF INACTIVATING BODY MALODOUR CAUSING MICROORGANISMS COMPRISING CORYNEBACTERIA. | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000001353-A1 | METHOD OF REDUCING OR PREVENTING MALODOUR | UNILEVER PLC (GB) | 2000-01-13 | — | — | WO | claimed |
| US-11660294-B2 | Compounds, compositions, and methods for the treatment and prevention of avian pathogenic E. coli (APEC) | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-30 | — | — | US | disclosed |
| CN-115590776-B | Hair growing and thickening essence composition and preparation method and application thereof | 广州禾力生物科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115590776-A | Hair-growing and hair-thickening essence composition and preparation method and application thereof | 广州禾力生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-114306173-A | Hair loss preventing essence and preparation method thereof | 广州华厦生物制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210330655-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND PREVENTION OF AVIAN PATHOGENIC E. COLI (APEC) | OHIO STATE INNOVATION FOUNDATION | 2021-10-28 | — | — | US | disclosed |
| US-20200062801-A1 | EPIMERIZATION-FREE N TO C SOLID-PHASE PEPTIDE SYNTHESIS | WAYNE STATE UNIVERSITY (US) | 2020-02-27 | — | — | US | disclosed |
| US-20130267680-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | STICHTING HET NEDERLANDS KANKERINSTITUUT | 2013-10-10 | — | — | US | disclosed |
| EP-2616479-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | Stichting Het Nederlands Kanker Instituut (NL) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012036551-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | STICHTING HET NEDERLANDS KANKERINSTITUUT (NL) | 2012-03-22 | — | — | WO | disclosed |
| US-20050244441-A1 | Cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1202628-B1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO CELTIQUE SA (LU) | 2004-10-13 | — | — | EP | disclosed |
| EP-1202628-A4 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO CELTIQUE SA (LU) | 2002-10-30 | — | — | EP | disclosed |
| EP-1202628-A1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | Euro-Celtique S.A. (LU) | 2002-05-08 | — | — | EP | disclosed |
| EP-0634408-B1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001011967-A1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2001-02-22 | — | — | WO | disclosed |
| US-5514773-A | PARASITICIDES, ANTHELMINTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267680-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | UBQLN1, UBQLN2, UBE3A | CYP1A2 2784/4885KDM4E 964/4885LMNA 4051/4885 |
| US-11660294-B2 | Compounds, compositions, and methods for the treatment and prevention of avian pathogenic E. coli (APEC) | FABP2, APC, AP1G1 | CYP1A2 4375/4885KDM4E 3571/4885LMNA 866/4885 |
| US-20210330655-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND PREVENTION OF AVIAN PATHOGENIC E. COLI (APEC) | FABP2, APC, AP1G1 | CYP1A2 4375/4885KDM4E 3571/4885LMNA 866/4885 |
| US-20200062801-A1 | EPIMERIZATION-FREE N TO C SOLID-PHASE PEPTIDE SYNTHESIS | NGLY1, ANPEP, NPPA | CYP1A2 4834/4885KDM4E 4173/4885LMNA 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.